Sa1875: VEDOLIZUMAB IS ASSOCIATED WITH REDUCED ADVERSE 30-DAY OUTCOMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE ON IMMUNE CHECKPOINT INHIBITOR-RELATED COLITIS | Publicación